Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.
about
Procarbazine, lomustine and vincristine for recurrent high-grade gliomaAdjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomasExternal beam radiation dose escalation for high grade gliomaHigh-grade glioma management and response assessment-recent advances and current challengesCurrent status of biomarker research in neurologyImaging of oligodendrogliomaRecent Molecular Advances in Our Understanding of GliomaClinical management of grade III oligodendrogliomaMalignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methodsModern brain tumor imagingOligodendroglioma: pathology, molecular mechanisms and markersMolecular biology of high-grade gliomas: what should the clinician know?Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.IDH1 and IDH2 mutations as novel therapeutic targets: current perspectivesGlioblastoma multiforme: emerging treatments and stratification markers beyond new drugsMolecular heterogeneity in glioblastoma: potential clinical implicationsMolecular Markers in Low-Grade Glioma-Toward Tumor ReclassificationPhase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813.Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumorsNeuro-oncology: Five new things.Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.Pros and cons of current brain tumor imagingParadoxical perfusion metrics of high-grade gliomas with an oligodendroglioma component: quantitative analysis of dynamic susceptibility contrast perfusion MR imaging.The role of initial chemotherapy for the treatment of adults with diffuse low grade glioma : A systematic review and evidence-based clinical practice guideline.[Epilepsy-associated tumors of the central nervous system: Epilepsy surgery and oncological aspects].Detecting tumor progression in glioma: Current standards and new techniques.Recent advances in subtyping tumors of the central nervous system using molecular data.Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study.Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial.Repurposing Mebendazole as a Replacement for Vincristine for the Treatment of Brain Tumors.IDH mutations: genotype-phenotype correlation and prognostic impact.Actionable molecular biomarkers in primary brain tumors.Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.Genetic landscape of extreme responders with anaplastic oligodendroglioma.Does early resection of presumed low-grade glioma improve survival? A clinical perspective.Morphologic spectrum of glial tumors: an increased trend towards oligodendroglial tumors in Pakistan1p/19q testing has no significance in the workup of glioblastomas.Central nervous system cancersMitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations.
P2860
Q24187436-A2A9EC18-04D1-4AE5-9E61-5F9C80EBDF35Q24194645-06B24B52-9B4B-4203-B3F1-7A3BA2428F82Q26470382-A80CDF16-4549-4225-978B-420E07638C5FQ26740664-257BBA2F-5371-4120-9717-F5ACB7A8EFBEQ26744505-0136DD91-E347-4D60-9DA3-7D31E2F2DD59Q26768596-F9E2BDCB-B28E-4363-9881-57287FF8A753Q26798442-EFF30609-5B0D-46C4-B6F5-2D8AF8E61DF3Q26801254-B5E34E64-30DB-4F10-AFEB-69DF88C61796Q26853516-3B9C4F1C-864B-47BF-AAFB-162F2EA10315Q27002344-BE2A2E42-53A0-4075-8602-4E9E9A7E0DC2Q27002448-465B515A-1220-43CC-A55D-D9F90F6BAC90Q27009190-89D3B889-71EF-4097-BD4D-D376DFFB6885Q27310843-45CF16B9-1E2D-470A-B9AC-EE2CC6DDD7B2Q27853175-1403A8AE-A6E7-44E1-A162-C900C4FC9A86Q28066926-89B18C16-BB55-4FCE-8177-F27F50F28942Q28082603-32C1FE15-09B9-4D72-AC3E-D3DA34B0D316Q28088605-FC3519E3-EC0E-4323-8866-5D8847517C54Q28383205-1B8A25A2-7578-4352-BDEE-3E26F22A3D07Q30275188-B965CBEC-0841-4C9E-ADEF-6284B6CE4333Q30370204-1DB83D4E-113F-41C0-B197-2E55C931AF6BQ30415098-A0599772-2B77-4D12-B7F6-5D69CDFAC026Q30836702-28593FE1-29E8-40B0-BF2A-CEAC5A4F2C47Q30860126-65600C22-C089-4131-8CFB-9FA1C5396DECQ30984368-27759C57-128D-4FFE-98BD-6B1F32C82F3EQ31016193-C91A4DE9-53CC-4093-AEC2-97DA74A13AA5Q31032523-70548C80-8CC6-4989-8276-6490D2C6BC2AQ31132701-806C4FAF-4DA3-45D9-B1CC-EA106072FF63Q31145092-8E963744-A574-4D8D-B067-FBDB650C0F2BQ33419628-371A215C-C7F3-4984-8DF7-F658DF4FA905Q33439379-2F3C07C0-521E-4C2C-8EA3-5D4EC4C78FF7Q33599587-E6818402-38FD-4673-AF92-0B76C66B2742Q33615867-EB44F85F-C0BD-4853-B031-DB70F2DA755DQ33772355-E8504EF1-B0B9-4E7A-AA4C-76C77051C69DQ33804713-00856098-3ADA-4580-A77B-7B532A4BD395Q33829209-ACF00F82-1EAB-4C27-848D-B97D3C659DB5Q33867304-DDE56D36-E0D0-45AE-A260-21F5AADC42D2Q33869758-266566CA-3FA6-4328-919D-8853F361C028Q33893445-0E953551-DEC6-41B4-92FB-C1FD1979FD4FQ34014740-D1632252-F7D3-4A2A-9A3F-73DF35D35D94Q34062043-7443B995-93EF-4531-9CCE-DDA8D743D305
P2860
Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Phase III trial of chemoradiot ...... ong-term results of RTOG 9402.
@ast
Phase III trial of chemoradiot ...... ong-term results of RTOG 9402.
@en
type
label
Phase III trial of chemoradiot ...... ong-term results of RTOG 9402.
@ast
Phase III trial of chemoradiot ...... ong-term results of RTOG 9402.
@en
prefLabel
Phase III trial of chemoradiot ...... ong-term results of RTOG 9402.
@ast
Phase III trial of chemoradiot ...... ong-term results of RTOG 9402.
@en
P2093
P2860
P921
P356
P1476
Phase III trial of chemoradiot ...... long-term results of RTOG 9402
@en
P2093
David Brachman
Edward Shaw
Gregory Cairncross
Jan Buckner
Karen Fink
Luis Souhami
Meihua Wang
Robert Jenkins
Walter Curran
P2860
P304
P356
10.1200/JCO.2012.43.2674
P407
P577
2012-10-15T00:00:00Z